Literature DB >> 8473487

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

D M Vigushin1, M B Pepys, P N Hawkins.   

Abstract

Plasma and whole-body turnover studies of human C-reactive protein (CRP), isolated from a single normal healthy donor and labeled with 125I, were undertaken in 8 healthy control subjects and 35 hospitalized patients including cases of rheumatoid arthritis, systemic lupus erythematosus, infections, and neoplasia. Plasma clearance of 125I-CRP closely approximated to a monoexponential function and was similar in the control and all patient groups. There was no evidence for accelerated clearance or catabolism of CRP in any of the diseases studied. The 19-h half-life was more rapid than that of most human plasma proteins studied previously, and the fractional catabolic rate was independent of the plasma CRP concentration. The synthesis rate of CRP is thus the only significant determinant of its plasma level, confirming the validity of serum CRP measurement as an objective index of disease activity in disorders associated with an acute-phase response. Approximately 90% of injected radioactivity was recovered in the urine after 7 d, and scintigraphic imaging studies with 123I-labeled CRP in 10 patients with different focal pathology showed no significant localization of tracer. The functions of CRP are thus likely to be effected predominantly in the fluid phase rather than by major deposition at sites of tissue damage or inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473487      PMCID: PMC288106          DOI: 10.1172/JCI116336

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  High efficiency iodination of monoclonal antibodies for radiotherapy.

Authors:  S J Mather; B G Ward
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

2.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

3.  C-reactive protein inhibits binding of platelet-activating factor to human platelets.

Authors:  J G Filep; F Hermán; E Kelemen; E Földes-Filep
Journal:  Thromb Res       Date:  1991-02-15       Impact factor: 3.944

4.  C-reactive protein decreases protein phosphorylation in stimulated human neutrophils.

Authors:  R Buchta; R Gennaro; M Pontet; M Fridkin; D Romeo
Journal:  FEBS Lett       Date:  1988-09-12       Impact factor: 4.124

5.  Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils.

Authors:  E G Shephard; S M Beer; R Anderson; A F Strachan; A E Nel; F C de Beer
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component.

Authors:  P Woo; J R Korenberg; A S Whitehead
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

7.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas.

Authors:  G D Reynolds; R P Vance
Journal:  Arch Pathol Lab Med       Date:  1987-03       Impact factor: 5.534

9.  Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions.

Authors:  I KUSHNER; M H KAPLAN
Journal:  J Exp Med       Date:  1961-12-01       Impact factor: 14.307

View more
  139 in total

Review 1.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 2.  Diagnostic markers of infection in neonates.

Authors:  P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747

Review 3.  Newer approaches to the diagnosis of early onset neonatal sepsis.

Authors:  U K Mishra; S E Jacobs; L W Doyle; S M Garland
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-05       Impact factor: 5.747

4.  To Compare the Efficacy of C-Reactive Protein and Total Leucocyte Count as Markers for Monitoring the Course of Odontogenic Space Infections.

Authors:  Rishi Bali; Parveen Sharma; Priya Ghanghas; Niti Gupta; Jay Dutt Tiwari; Abhiroop Singh; Nitin Sapra; Disha Goyal
Journal:  J Maxillofac Oral Surg       Date:  2016-10-21

5.  Change in cardiovascular risk factors with progression of kidney disease.

Authors:  Linda F Fried; Ronit Katz; Mary Cushman; Mark Sarnak; Michael G Shlipak; Lewis Kuller; Anne B Newman
Journal:  Am J Nephrol       Date:  2008-10-24       Impact factor: 3.754

Review 6.  Targeting inflammation: impact on atherothrombosis.

Authors:  Maria Giulia Marini; Chiara Sonnino; Marco Previtero; Luigi M Biasucci
Journal:  J Cardiovasc Transl Res       Date:  2013-12-11       Impact factor: 4.132

7.  To Evaluate and Compare Periodontal Disease and Smoking as a Parallel Risk Factor for Systemic Health by Gauging the Serum C-Reactive Protein Levels.

Authors:  Ruchi Dinesh Raval; Payal Sharma; Sarath Chandran; Dharmesh Vasavada; Priyadarshini Nadig; Gaurav Bakutra
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Endothelial injury markers before and after nasal continuous positive airway pressure treatment for obstructive sleep apnoea hypopnoea syndrome.

Authors:  Maria Wilczynska; Samuel Rice; Gareth Davies; Keir E Lewis
Journal:  Sleep Breath       Date:  2013-12-11       Impact factor: 2.816

9.  Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli.

Authors:  M B Pepys; S E Booth; G A Tennent; P J Butler; D G Williams
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.